Summary of adverse events by histology and treatment regimen
| Histology | Treatment regimen | Grade 3/4 adverse event rate | |
| Treatment related | Non-treatment related | ||
| DDLPS | Nivolumab (n=15) | 4 (26.6%) | 11 (73.3%) |
| Nivolumab with ipilimumab (n=14) | 2 (14.3%) | 5 (35.7%) | |
| UPS | Nivolumab (n=13) | 2 (15.4%) | 8 (61.5%) |
| Nivolumab with ipilimumab (n=14) | 3 (21.4%) | 7 (50%) | |
| GIST | Nivolumab (n=10) | 2 (20.0%) | 6 (60%) |
| Nivolumab with ipilimumab (n=11) | 5 (45.5%) | 4 (36.4%) | |
DDLPS, dedifferentiated liposarcoma; GIST, gastrointestinal stromal tumor; UPS, undifferentiated pleomorphic sarcoma.